StreetAlpha.app
Home › Stocks › RCUS

Arcus Biosciences, Inc. (RCUS)

Healthcare
$16.40
▼ −2.84%
LAST CLOSE · NOV 17

Arcus Biosciences develops investigational cancer medicines for patients and the doctors who treat them. It last closed at $16.40 on Nov 17, down 2.84% on the day. The average 12-month price target from 4 analysts is $44.25 (+169.8% from the last close), with a high of $50.00 and a low of $41.00. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell). In the past 30 days there were 3 dark pool prints totaling $3.4M, the largest $2.0M.

AI Auto Pilots
Is RCUS in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$100.0M
−58.3% vs a year ago
Net income
−$453.0M
−453.0% margin
EPS (diluted)
−$3.64
Free cash flow
−$466.0M
−466.0% margin
Valuation
Market cap
$2.4B
144.0M shares
P/E
–
No P/E while losing money
Price to sales
23.6
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$151.0M
At Sep 30
Debt
$102.0M
At Sep 30
Shareholder equity
$358.0M
Shares outstanding
144.0M
At Oct 29
Fiscal year endsDecember
ExchangeNYSE
Financials history
FY2021: $383.0M$383.0MFY2021FY2022: $112.0M$112.0MFY2022FY2023: $117.0M$117.0MFY2023FY2024: $258.0M$258.0MFY2024FY2025: $247.0M$247.0MFY2025

From RCUS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 4 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
4firms
4 Buy0 Hold0 Sell
Each firm's latest rating on RCUS in the past 90 days
Average 12-month target
$44.25
▲ 169.8% upside

Based on 4 analysts who set a price target on RCUS in the past 90 days. The average target is $44.25, with a high of $50.00 and a low of $41.00, compared with the last close of $16.40.

Low $41.00Avg $44.25High $50.00
Blue marker: last close $16.40
Highest target$50.00
Average target$44.25
Lowest target$41.00
Latest rating changes
WedbushTarget lowered
Nov 5Buy$49 → $45
CitigroupMaintained
Oct 21Buy$50
Truist SecuritiesTarget raised
Oct 21Buy$40 → $41
WedbushTarget raised
Oct 21Buy$43 → $49
JP MorganInitiated
Oct 14Buy$41
DateFirmActionRatingPrice target
Nov 5WedbushTarget loweredBuy$49 → $45
Oct 21CitigroupMaintainedBuy$50
Oct 21Truist SecuritiesTarget raisedBuy$40 → $41
Oct 21WedbushTarget raisedBuy$43 → $49
Oct 14JP MorganInitiatedBuy$41
Loading…

Technical Analysis

RCUS · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 11% below its 20 day and 35% below its 50 day average. It is 49% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 31), near oversold. The nearest support is the 52 week low at $16.33, and the nearest resistance the Pivot at $16.60.

Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityNormal, 7.0%/day
Key levels
$31.7452 week high+93.5%
$25.63100 day average+56.3%
$24.42200 day average+48.9%
$22.1150 day average+34.8%
$19.02Swing high (Oct 29)+16.0%
$18.2520 day average+11.3%
$16.87Pivot R1+2.9%
$16.60Pivot+1.2%
$16.40Last close
$16.3352 week low−0.4%
$16.13Pivot S1−1.6%
Indicators
RSI (14)31.23Weak, oversold below 30Neutral
MACD-1.45Above its signal lineBullish
Stochastic7.1Near the bottom of its rangeOversold
ADX (14)31.1Trending down
Williams %R-97.9Oversold below −80, overbought above −20Oversold
CCI (20)-200.9Oversold below −100, overbought above 100Oversold
Rate of change−13.4%Change over 10 sessionsBearish
ATR (14)$1.14Typical daily range, 7.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for RCUS

What happened before

See how RCUS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow RCUS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How RCUS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in RCUS in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
3
Notional
$3.4M
Largest print
$2.0M
Loading…

RCUS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲132 buying vs 102 selling
  • ▲Held by funds +1.6 pts
  • ▲Funds holding +14
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding244230+6.1%
In funds' top 1056−16.7%
Held by funds86.8%85.2%+1.6 pts
New / increased47 / 8543 / 87+1.5%
Reduced / sold out72 / 3063 / 24+17.2%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See RCUS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RCUS is in one of them and how their past RCUS trades turned out.

RCUS in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered RCUS in an article yet. Here's the latest on the wider market.

RCUS Congress Trades

All congress trades →
Trades, 12 months
2
Buys
0
0%
Sells
2
100%
People
1
Last filed Sep 22
Who traded RCUS · since 2026
Latest 2 filings
$1K – $15KTraded Jul 29, 2026Filed Sep 22, 2026
$15K – $50KTraded May 15, 2026Filed Jul 1, 2026
PersonTypeAmountTradedFiledDelay
Donald J TrumpExecutive branchSell$1K – $15KJul 29, 2026Sep 22, 202655 d
Donald J TrumpExecutive branchSell$15K – $50KMay 15, 2026Jul 1, 202647 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Arcus Biosciences

Arcus Biosciences is a biopharmaceutical company based in Hayward, California. It develops investigational medicines, mainly for cancer, and tests them in clinical trials carried out with contract research organizations and trial sites. Its products are still investigational, and it works with partners such as AstraZeneca, Gilead and Taiho on some of its programs. Its intended users are cancer patients and the doctors who treat them.

Headquarters
Hayward, CA
Founded
2015